Anti-Fibrinolytic Drugs - Belgium

in Belgium, a country renowned for its rich history and cultural heritage, is not immune to the advancements in the global pharmaceutical industry.
Within this context, the Anti-Fibrinolytic Drugs market in Belgium is poised for significant growth.
According to projections, the revenue in this market is expected to reach US$91.51m by the year 2024.
This promising trajectory is further bolstered by an estimated annual growth rate (CAGR 2024-2029) of 4.19%, leading to a market volume of US$112.40m by 2029.
In the global landscape, it is worth noting that United States will continue to dominate the Anti-Fibrinolytic Drugs market, generating a staggering revenue of US$9.86bn in 2024.
This underscores the significant market share held by United States in this particular market.
The demand for anti-fibrinolytic drugs in Belgium is on the rise due to the country's aging population and increasing prevalence of cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Belgium, a country in Western Europe, has been experiencing a significant rise in the Anti-Fibrinolytic Drugs market.

Customer preferences: The Anti-Fibrinolytic Drugs market in Belgium is primarily driven by the rising prevalence of bleeding disorders, such as hemophilia and von Willebrand disease. Additionally, the increasing number of surgeries being performed in the country has also contributed to the growth of this market. Patients undergoing surgeries require Anti-Fibrinolytic Drugs to prevent excessive bleeding during and after the procedure.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Belgium is the shift towards personalized medicine. With advancements in technology and research, healthcare providers are now able to tailor treatment plans based on an individual's genetic makeup, which has resulted in more effective and efficient treatment outcomes. Moreover, the market is witnessing an increase in the number of product launches by key players, which is further driving market growth.

Local special circumstances: Belgium has a well-established healthcare system that provides universal coverage to its citizens. This has resulted in higher accessibility to healthcare services, including medicines. Additionally, the country has a high prevalence of bleeding disorders, which has led to an increased demand for Anti-Fibrinolytic Drugs. Furthermore, the presence of key players in the country has also contributed to the growth of the market.

Underlying macroeconomic factors: The Belgian economy has been growing steadily over the past few years, which has resulted in an increase in healthcare spending. This has provided a boost to the Anti-Fibrinolytic Drugs market, as healthcare providers are now able to invest more in research and development, as well as the procurement of medicines. Additionally, the aging population in the country has also contributed to the growth of the market, as older individuals are more prone to bleeding disorders and require Anti-Fibrinolytic Drugs for treatment.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.